Navigation Links
MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
Date:7/13/2009

l likely remain an important cause of neurological disease for the foreseeable future. Since 2002, more than 4,500 cases of clinical WNV infection have been reported in Canada. No effective therapy or vaccine is available for humans. For more information about WNV, including maps of WNV activity, please visit www.cdc.gov/WestNile.

About MacroGenics, Inc.

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. Since its founding in 2000, the company has built a fully-integrated set of capabilities in monoclonal antibody product development. The company's product development efforts leverage three proprietary technology platforms: (1) cancer stem-like cells; (2) Dual Affinity Re-Targeting (DART), which allows the company to incorporate multiple specificities within a single molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions. These powerful sets of capabilities and technology platforms have enabled MacroGenics to build a proprietary pipeline of innovative product candidates. The company's lead program, teplizumab, is an anti-CD3 antibody being developed for the treatment of autoimmune diseases. In October 2007, MacroGenics and Eli Lilly announced a global strategic alliance to develop and commercialize teplizumab as well as other potential next-generation anti-CD3 molecules. For more information about MacroGenics, please visit www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions a
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Paulo F. Costa Joins MacroGenics Board of Directors
2. MacroGenics Appoints New Vice President of Business Development
3. MacroGenics Raises $25M in Series D-2 Financing
4. MacroGenics Acquires Raven Biotechnologies
5. Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman
6. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
7. Mirixa Corporation Announces Key New Hires
8. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
9. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 New ... most innovative thought leaders of the medical device ... East conference and expo, from June 18-20 in ... (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... deliver industry professionals practical presentations and implementable solutions ...
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- Aridis is ... reached with Switzerland -based Kenta ... human monoclonal antibody (mAb) products, and technologies. This ... products for treatment of infections by common pathogens ... aureus , Pseudomonas aeruginosa , Acinetobacter ...
(Date:5/17/2013)... 2013 The paradigm of ‘one drug, ... that can help predict the adverse and therapeutic effects ... Head of Computational Biology at the Genomics Laboratory, Covance, ... ensure high-quality genomics when used as part of the ... complex data sets to identify key clinical targets even ...
(Date:5/17/2013)... IAC Industries wants to share with you the success ... set up and furnish a research lab knowing that the ... year’s time. How does a company make choices in lab ... is efficient and cost-effective? , The solution was the ... planners at DisperSol determined that the concept of modular lab ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... Mass., July 23 NxStage Medical,Inc. (Nasdaq: ... today announced ongoing public access to current summary,information ... end-stage,renal-disease (ESRD) who undergo hemodialysis at home on ... to the conventional regimen of therapy,received three times ...
... WILMINGTON, Del., July 23 More than a ... AZN ) to inquire about the,company,s prescription savings ... pharmacists, according to a year-long survey of more ... percent of the patients who called,AstraZeneca,s information center ...
... Future, CAMBRIDGE, Mass., July 23 Genzyme Corporation,(Nasdaq: ... growth in the second,quarter, along with significant progress in ... to approximately $1.171 billion from,$933.4 million in last year,s ... areas of the business., GAAP net income was ...
Cached Biology Technology:NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 2NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 3NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 4NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population 5AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 2AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 3Genzyme Reports Strong Second-Quarter Growth 2Genzyme Reports Strong Second-Quarter Growth 3Genzyme Reports Strong Second-Quarter Growth 4Genzyme Reports Strong Second-Quarter Growth 5Genzyme Reports Strong Second-Quarter Growth 6Genzyme Reports Strong Second-Quarter Growth 7Genzyme Reports Strong Second-Quarter Growth 8Genzyme Reports Strong Second-Quarter Growth 9Genzyme Reports Strong Second-Quarter Growth 10Genzyme Reports Strong Second-Quarter Growth 11Genzyme Reports Strong Second-Quarter Growth 12Genzyme Reports Strong Second-Quarter Growth 13Genzyme Reports Strong Second-Quarter Growth 14Genzyme Reports Strong Second-Quarter Growth 15Genzyme Reports Strong Second-Quarter Growth 16Genzyme Reports Strong Second-Quarter Growth 17
(Date:5/16/2013)... MD FASEB MARC (Maximizing Access to Research ... for The Society for Developmental Biology (SDB) 72nd ... 2013. These awards are meant to promote the ... groups into the mainstream of the basic science ... scientists at the SDB 2013 Annual Meeting. , ...
(Date:5/16/2013)... the stability of today,s largest ice sheets in Greenland and ... ago, for example when Earth was going through a ... high sea level due to ice sheet collapse at that ... if the world,s largest ice sheets collapsed in the past, ... progressively warming world. , However, a new groundbreaking study ...
(Date:5/16/2013)... -- Injectable nanoparticles developed at MIT may someday ... diabetes to constantly monitor their blood-sugar levels and ... designed to sense glucose levels in the body ... insulin, thereby replacing the function of pancreatic islet ... 1 diabetes. Ultimately, this type of system could ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... on algae, researchers at UT Southwestern Medical Center have found ... responsible for a cell's response to external signals. , Cilia ... sperm cells to make fertilization possible, line the nose to ... , With such a range of abilities, cilia serve ...
... someone say 'yes', coffee can help. Moderate amounts ... to which we can be persuaded, finds research published ... The Australian researchers from the University of Queensland found ... attend to, and agree with, persuasive arguments. , The ...
... cheaper, more effective liver cancer treatment, reports Lisa Richards ... over 2,800 people in the UK each year, of ... Surgery is the best option, but is unsuitable for ... chemotherapy. The American Cancer Society estimates that 18,510 new ...
Cached Biology News:'Cellular antennae' on algae give clues to how human cells receive signals 2
The Saturn 2200 answers your GC/MS questions with the CP-3800 GC and the 2000 Series Ion Trap MS! These components create a platform for the worlds most versatile GC and flexible MS. Both deliver une...
... The EZ DNA Methylation Kit uses ... method for DNA methylation analysis. The kit ... that takes place between cytosine and sodium ... The EZ DNA Methylation Kits innovative in-column ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
Biology Products: